ATS's Earnings Call: Margin Timelines Clash, Transportation Role Disputed

Date of Call: Aug 6, 2026

Financials Results

• Revenue: Adjusted revenue down 5% YOY
• EPS: Adjusted EPS $0.35 per share
• Gross Margin: Growth margin 30%, an 18 basis point increase YOY
• Operating Margin: Adjusted earnings from operations $68.1M, down 13.4% YOY

Guidance:

• Q2 revenue expected in the range of $660 million to $700 million.
• Expect margins to strengthen through the second half as backlog converts and cost actions take effect.
• Full-year modest organic revenue growth remains achievable, dependent on timing of larger customer awards in the second half.
• Expect to operate within net debt to adjusted EBITDA ratio target of 2 to 3 times through fiscal 2027.
• CapEx, including technology infrastructure and intangible investments, expected between $70 million and $90 million for fiscal 2027.

Quick Backtesting Tool

SymbolATS

Strategy

Select

Backtest Range

Past 5 years

Run backtestMore Backtesting Ideas

Business Commentary:

Revenue and Backlog Trends:

• ATS Corporation reported Q1 adjusted revenues were down 5% year-over-year, reflecting a planned reduction in large-scale automotive work. The order backlog at the end of the quarter was approximately $1.9 billion.
• The decline in revenue was due to the planned reduction in transportation-related activity, while the backlog remained healthy across chosen markets, indicating strong underlying demand.

Profitability and Margin Improvement:

• Adjusted earnings from operations were $68.1 million, down 13.4% from the previous year, primarily due to lower revenues. Growth margin for Q1 was 30% of adjusted revenues, showing an 18 basis point increase year-over-year.
• The margin improvement was driven by higher-margin aftermarket service revenues, despite lower revenues in radiopharma and nuclear segments.

Cost Transformation and Margin Expansion:

• The company initiated an 18-month fixed cost transformation program aiming to achieve approximately half of the margin improvement needed to reach a 15% operating margin target, with an estimated $20 million in annualized savings from the initial European phase.
• The program focuses on reducing facility overhead, indirect expenses, and SG&A to address excess capacity and operating infrastructure, particularly in Europe.

Order Activity and Market Dynamics:

• Order bookings for Q1 were $656 million, down 5.3% year-over-year, influenced by large nuclear project awards in the prior year and timing of project execution.
• The company expects order activity to recover in the second half of the year, driven by strong customer engagement in life sciences, food and beverage, and energy markets.

Sentiment Analysis:

Overall Tone: Positive

• "My overall optimism is reflected in positive outcomes across several areas of the business." "I am confident in the growth profile and the underscores for safe and high quality food production and contribute to energy." "We have a clear plan, and now it's about execution. And I'm confident in our ability to translate that into improved performance and meaningful value creation."

Q&A:

• Question from Sabahat Khan (RBC Capital): Could you give more color on orders and the nature of any revenue slippage into future periods needed to deliver on expectations for modest growth this year?
  Response: Achieving modest organic revenue growth depends on the timing of larger customer awards in the second half; markets are inherently lumpy short-term but healthy long-term, and backlog conversion velocity will need to improve.

• Question from Cherilyn Radborn (TD Cowan): Was the major cost transformation plan necessary, and was cost reduction part of your initial thesis when you joined ATS?
  Response: Cost reduction was partly known, but the comprehensive site review identified more opportunities for savings and efficiency, particularly in addressing overcapacity and underutilization while balancing investment in growth markets.

• Question from Michael Glension (Raymond James): What is the margin profile of the existing backlog, and what should we think about margins exiting the 18-month transformation program?
  Response: No material difference in margin profile between current backlog and future expectations; significant margin improvement will occur within the 18-month horizon, with the full path to 15% operating margin requiring continued actions post-program.

• Question from Justin Keywood (Stifel): Can you provide context on radiopharmaceuticals as a sub-segment percentage of sales, book to bill, and the operating margin target?
  Response: Radiopharma is the fastest growing and now the largest part of life sciences backlog, with a strong pipeline; the long-term operating margin target is 15%, with the cost transformation program aiming for ~250 basis points of improvement.